Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Raw Materials (2019 - 2025)

Ptc Therapeutics (PTCT) has 7 years of Raw Materials data on record, last reported at $2.3 million in Q4 2025.

  • For Q4 2025, Raw Materials fell 9.73% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $2.3 million, down 9.73%, while the annual FY2025 figure was $2.3 million, 9.73% down from the prior year.
  • Raw Materials reached $2.3 million in Q4 2025 per PTCT's latest filing, up from $2.2 million in the prior quarter.
  • Across five years, Raw Materials topped out at $2.7 million in Q3 2024 and bottomed at $678000.0 in Q1 2021.
  • Average Raw Materials over 5 years is $1.5 million, with a median of $1.3 million recorded in 2022.
  • Peak YoY movement for Raw Materials: decreased 26.92% in 2023, then soared 201.87% in 2024.
  • A 5-year view of Raw Materials shows it stood at $1.4 million in 2021, then decreased by 23.98% to $1.1 million in 2022, then decreased by 11.69% to $952000.0 in 2023, then soared by 166.6% to $2.5 million in 2024, then decreased by 9.73% to $2.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $2.3 million in Q4 2025, $2.2 million in Q3 2025, and $2.2 million in Q2 2025.